Showing results (131-140 of 230) with videos related to
Sort By:
Pageof 23
Cancer|March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysisChee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumorsRichard T Penson, Don S Dizon, Stephen A Cannistra, et al.JAMA Oncology|October 11, 2019
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical TrialJoyce F Liu, Christina Herold, Kathryn P Gray, et al.Plos One|February 21, 2012
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancerStefan Bentink, Benjamin Haibe-Kains, Thomas Risch, et al.American Journal of Obstetrics and Gynecology|June 18, 2019
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancerAllison Gockley, Alexander Melamed, Angel Cronin, et al.Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.Gynecologic Oncology|July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics dataLauren Roller, Ningxuan Zhou, Isha Atre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II StudyNicoletta Colombo, Toon Van Gorp, Ursula A Matulonis, et al.Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.Pageof 23